Racetam Family (Piracetam and Analogues)
NootropicThe medical score (62) reflects the mixed clinical evidence and methodological weaknesses of piracetam studies [s6, s13], while the community (72) places greater weight on the subjectively stronger effects of newer racetams such as aniracetam and phenylpiracetam [c1, c2, c3]. The discrepancy arises because user reports frequently describe uncontrolled polypharmacy with choline stacks, which amplifies perceived effects.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Piracetam is the best-studied racetam, with meta-analyzed evidence in cognitive impairment and cortical myoclonus — but evidence for healthy users is essentially absent. For aniracetam, oxiracetam, pramiracetam, and phenylpiracetam, robust human trial data barely exist; community reports are intriguing but purely anecdotal. Phenylpiracetam loses its effect rapidly with daily use, and nearly all racetams require a choline source (e.g., Alpha-GPC) to prevent headaches. In Germany, piracetam is prescription-only; all other racetams occupy a legal grey zone with uncontrolled product quality from grey-market sources.
Description
Synthetic pyrrolidone derivatives for cognitive enhancement; piracetam is the oldest and most extensively studied member of the class [s2, s3].
The racetam family comprises a group of structurally related synthetic compounds, all containing a pyrrolidone core. The original racetam, piracetam, was synthesized in the 1960s by Corneliu E. Giurgea and coined the term "nootropic" [s3]. Since then, numerous analogues have been developed differing in potency, pharmacokinetics, and activity profile [s4, s5]. The most clinically relevant members are: - **Piracetam**: Best-known member; prescription-only in Germany for cognitive disorders and cortical myoclonus; most extensive evidence base [s1, s6]. - **Aniracetam**: Prescription-only in Europe; lipophilic, faster onset of action; potential anxiolytic properties; no FDA approval [s7, s8]. - **Oxiracetam**: No longer clinically approved; primarily used in research; considered more potent than piracetam in the memory domain [s4, s5]. - **Pramiracetam**: Very high potency at low doses; few controlled human studies [s4, s5]. - **Phenylpiracetam**: The only racetam with stimulant properties due to its phenethylamine structure; atypical dopamine reuptake inhibitor [s4]. - **Fasoracetam / Coluracetam / Nefiracetam**: Newer derivatives with little or no clinical evidence in humans; some investigated only in animal studies [s4, s5]. The clinical efficacy of racetams for cognitive impairment and dementia is controversial. A Cochrane review found that piracetam can improve the global clinical impression but shows no consistent effects on objective memory parameters [s6]. For cortical myoclonus, piracetam is considered a well-supported therapeutic option [s10].
Legal Status (DE)
Piracetam is a prescription-only medicinal product in Germany pursuant to § 48 AMG in conjunction with Annex 1 of the Arzneimittelverschreibungsverordnung (AMVV). The AMVV — enacted on the basis of the Arzneimittelgesetz (AMG) — specifies which active substances may only be dispensed on medical prescription. The BfArM is responsible for applications to amend prescription requirements; amendments are published in the Bundesgesetzblatt Part I. Non-approved racetams (e.g., aniracetam, oxiracetam, pramiracetam, phenylpiracetam in Germany) fall into a legal grey area: they are neither approved as medicinal products nor explicitly prohibited, but when placed on the market commercially they are treated as unauthorised medicinal products under § 21 AMG and are therefore not legally marketable without approval [s1].
Mechanism of Action
Racetams have no universally accepted mechanism of action [s4]. The principal postulated mechanisms are: 1. **AMPA/NMDA receptor modulation**: Piracetam and related racetams positively modulate AMPA and NMDA receptors, enhancing glutamatergic neurotransmission and potentially improving synaptic plasticity [s3, s4]. 2. **Cholinergic modulation**: Piracetam increases acetylcholine activity via muscarinic receptors and enhances ACh uptake; this is considered the primary mechanism of cognitive effects [s1, s2, s3]. 3. **Membrane fluidity**: Piracetam interacts with phospholipids of the cell membrane and improves their fluidity, facilitating neuronal signal transduction [s1, s2]. 4. **Cerebral blood flow and metabolism**: Piracetam increases cerebral blood flow, cerebral oxygen consumption, and glucose metabolism [s2, s11]. It additionally reduces platelet aggregation [s2]. 5. **Ion channel modulation**: Some racetams influence ion channels, thereby increasing neuronal excitability [s2, s11]. 6. **Phenylpiracetam**: Acts as an atypical dopamine reuptake inhibitor with stimulant properties; unique profile within the family [s4]. 7. **Fasoracetam**: Proposed to upregulate GABA-B receptors, thereby mediating anxiolytic effects [c1]. GABA receptors are not directly affected by piracetam [s3].
Dosing
Kognitive Beeinträchtigung / Demenz (Piracetam)
- Dose
- 2400–8000 mg/day elemental piracetam, divided into 2–3 doses
- Frequency
- 2–3× täglich
- Route
- oral
- Duration
- 6–52 Wochen (gemäß klinischen Studien)
- Timing
- With meals
- With food
- empfohlen
Kortikaler Myoklonus (Piracetam)
- Dose
- 16,800–24,000 mg/day, divided into multiple doses
- Frequency
- mehrmals täglich
- Route
- oral
- Duration
- Langzeit (bis zu mehreren Jahren)
- Timing
- Evenly distributed throughout the day
- With food
- empfohlen
Kognitive Förderung off-label (Aniracetam)
- Dose
- 750 mg, 2–3× daily (community protocol)
- Frequency
- 2–3× täglich
- Route
- oral
- Duration
- Zyklusweise, keine Langzeitdaten
- Timing
- Morning, possibly midday; avoid evening due to potential sleep disturbances
- With food
- optional
Kognitive Förderung off-label (Phenylpiracetam)
- Dose
- 100 mg per dose, maximum 2× per week
- Frequency
- Bedarfsweise, nicht täglich (Toleranzentwicklung)
- Route
- oral
- Duration
- Zyklisch; keine Daueranwendung
- Timing
- Morning or late morning; not in the evening
- With food
- optional
Piracetam: up to 24 g/day in clinical myoclonus studies without increased organ toxicity [s10, s12]. No established upper limits from controlled human studies exist for aniracetam, oxiracetam, pramiracetam, or newer racetams [s4, s5].
All racetams are combined by the community with a choline source (e.g., Alpha-GPC 300 mg or CDP-choline) to minimise racetam-induced headaches [c1, c2, c3]. For Germany: piracetam is legally available by prescription only; all other racetams mentioned are not approved as dietary supplements [s8, s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Kopfschmerzen Increased acetylcholine turnover leads to relative choline deficiency; most common user complaint; can be minimized by choline supplementation [s1, c1]. | gelegentlich | leicht |
| Gastrointestinale Beschwerden (Übelkeit, Erbrechen, Diarrhö) Documented in clinical studies in fewer than 10% of participants; more frequent at high piracetam doses [s12, s14]. | gelegentlich | leicht |
| Schlafstörungen / Insomnie Reported particularly with stimulating racetams (phenylpiracetam, oxiracetam) and with evening administration [s14, c3]. | gelegentlich | leicht |
| Reizbarkeit / Nervosität / Agitation Possible due to increased neuronal excitability via glutamatergic modulation [s14, c2]. | selten | leicht |
| Schwindel, verschwommenes Sehen, Hautausschlag Individual cases documented in post-marketing reports [s14]. | selten | leicht |
| Paradoxe Sedierung / Müdigkeit (Piracetam) Reported in individual users, particularly at high doses or as an initial response; mechanism unclear [s14, c4]. | selten | leicht |
| Erhöhte Blutungsneigung Piracetam reduces platelet aggregation; relevant with concurrent anticoagulation or bleeding tendency [s2, s12]. | theoretisch | moderat |
Contraindications
Piracetam is renally eliminated; accumulates in renal impairment; dose adjustment or contraindication required [s12].
Antiplatelet effect of piracetam increases bleeding risk [s2, s12].
Insufficient safety data; piracetam crosses the placenta; use is contraindicated [s12].
Piracetam showed no efficacy in children with Down syndrome; general safety data in children insufficient [s6, s12].
Single case report of an adverse reaction to piracetam in a hypothyroid child; caution advised in thyroid disorders [s12].
Additive antiplatelet effects of piracetam may increase bleeding risk [s2].
Interactions
Synergistic
Racetams increase acetylcholine turnover; choline sources compensate for the increased demand and reduce racetam-induced headaches [c1, c2].
Frequently used as a stack in the nootropics community; no controlled human data on combinations available [c1].
ALCAR synergistically complements racetams through neuroprotective properties and support of cognitive processes. It also helps compensate for the increased acetylcholine turnover induced by racetams when used together with a choline source.
Bacopa monnieri is frequently combined with racetams in the nootropics community. The combination is purported to additively enhance memory consolidation and learning capacity, as both substances utilize distinct mechanisms.
CDP-choline supplies choline as a precursor for acetylcholine synthesis, compensating for the increased acetylcholine turnover induced by racetams. Studies show that the combination of CDP-choline and piracetam at subtherapeutic doses produces synergistic effects on memory consolidation.
Ashwagandha exerts adaptogenic and anxiolytic effects via GABAergic and serotonergic pathways, while racetams primarily modulate the cholinergic system. These complementary mechanisms are utilized in the nootropics community for combined improvements in focus, stress resilience, and cognition.
BPC-157 demonstrates neuroprotective properties in animal studies by promoting neuroregeneration and angiogenesis. Combination with racetams may offer additive neuroprotective effects, as both substances utilize distinct neuroprotective pathways.
Panax ginseng acts as an adaptogen and supports cognitive function via ginsenosides that modulate neurotransmission. The combination with racetams is used in the nootropics community for additive cognitive enhancement.
L-theanine promotes relaxed alertness through modulation of GABA and glutamate receptors and may attenuate the stimulating properties of phenylpiracetam. The combination is purported to promote focused concentration without excessive stimulation.
Caution
Piracetam inhibits platelet aggregation; additive bleeding risk with combination therapy [s2, s12].
Phenylpiracetam has stimulant properties; combination with other stimulants may lead to overstimulation, palpitations, and sleep disturbances [s4, c3].
Piracetam is used as add-on therapy in myoclonic epilepsy; interactions with valproate and other antiepileptics are possible; use only under medical supervision [s10].
Studies
Tier A — High Evidence
Outcome: Memory function in adults with cognitive impairment
Effect Size: Piracetam treatment group (n=442) vs. placebo; effect direction positive, but limited effect size [s13].
Outcome: Symptom relief in progressive myoclonic epilepsy
Effect Size: Significant reduction of myoclonic symptoms under piracetam vs. placebo at three dosage levels [s10].
Outcome: Cognitive function and clinical global impression in dementia/cognitive impairment
Effect Size: Improvement in clinical global impression significant; objective memory parameters not consistently improved; methodological weaknesses in many included studies [s6].
Tier B — Moderate Evidence
Outcome: Classification and mechanism of action of the racetam family
Effect Size: No uniform mechanism of action class; three subgroups based on structure and clinical application [s4].
Outcome: Safety profile of piracetam in acute stroke (high doses)
Effect Size: No increased organotoxicity; adverse effects comparable between piracetam and placebo groups [s12].
Outcome: Overview of piracetam-like substances, clinical applications, and safety
Effect Size: Piracetam subgroup 1 (incl. aniracetam, oxiracetam, pramiracetam, phenylpiracetam): human studies available for piracetam; aniracetam/oxiracetam no longer in clinical use; others have few human studies [s5].
Tier C — Low Evidence
Outcome: Aniracetam: neuroprotective and anxiolytic properties
Effect Size: Preclinical evidence strong; controlled human data very limited [s7].
Community Evidence
Top reported benefits
- Improved concentration and mental processing speed (oxiracetam, piracetam)
- Anxiety reduction and social ease (aniracetam, fasoracetam)
- Stimulant effect and physical energy (phenylpiracetam)
- Improved memory recall (pramiracetam, oxiracetam)
- Improved verbal fluency and communication
Top reported issues
- Headaches without a choline source (very frequently reported)
- Rapid tolerance development with phenylpiracetam
- Piracetam described as ineffective by many users
- Sleep disturbances when taking stimulating racetams in the evening
- Procurement difficulties and unclear product quality from grey market sources
Several users report piracetam to be the most disappointing racetam, showing no measurable effects [c4]. The quality of grey-market-sourced racetams is uncontrolled. Phenylpiracetam rapidly loses efficacy with daily use. In Germany, acquisition without a prescription is not clearly regulated from a legal standpoint [s8, s9].
Scientific Sources
- What is the mechanism of Piracetam?
Patsnap Synapse Editorial Team (2023). Patsnap Synapse (Industry Review)CLink - Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo
Koskiniemi M, Van Vleymen B, Hakamies L, et al. (1998). Journal of Neurology, Neurosurgery, and PsychiatryAPMID:9527146DOI - Nootropikum – Wikipedia (Deutsch)
Wikipedia Contributors (2024). WikipediaCLink - The clinical safety of high-dose piracetam – its use in the treatment of acute stroke
De Deyn PP, Reuck JD, Deberdt W, et al. (1999). CNS DrugsBPMID:10338106DOI - Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis
Costa AS, Araujo LM, Nunes E, et al. (2024). European Journal of NeurologyAPMID:38878641DOI - Racetam Safety and Side Effects: Pharmacokinetic Risk Assessment
Supermindhacker Editorial (2022). Supermindhacker.comCLink - Piracetam – Wikipedia (Deutsch)
Wikipedia Contributors (2024). WikipediaCLink - Piracetam – Wikipedia (English)
Wikipedia Contributors (2024). WikipediaCLink - Piracetam and Piracetam-Like Drugs: From Basic Science to Novel Clinical Applications to CNS Disorders
Malykh AG, Sadaie MR (2010). DrugsBPMID:20166767DOI - Piracetam and Piracetam-Like Drugs: From Basic Science to Novel Clinical Applications to CNS Disorders (ResearchGate)
Malykh AG, Sadaie MR (2010). DrugsBPMID:20166767DOI - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans T, Wilsher CR, Danniau A, et al. (2002). Dementia and Geriatric Cognitive DisordersAPMID:12006732DOI - Aniracetam: An Evidence-Based Model for Preventing Cognitive and Emotional Disorders
Koliaki C, Messinis L, Lyros E, et al. (2024). PMC / FrontiersBLink - Nootropika legal in Deutschland & EU?
Noodoc.com Editorial (2023). Noodoc.comCLink - Classification Status of Racetams – Medsafe New Zealand
Medsafe New Zealand (2020). Medsafe New ZealandBLink
Community Sources
Storage
Unopened
Store dry, at room temperature (15–25 °C), protected from light and moisture.
Opened
Keep container tightly closed; avoid moisture; powder forms are particularly sensitive.
Notes
Racetam powders may be hygroscopic and should be stored in airtight containers. No specific stability data from published studies are available.